Le produit a bien été ajouté au panier.

discount label
H-EGSRNQDWL-OH
Vue en 3D

Biosynth logo

H-EGSRNQDWL-OH

Ref. 3D-PP45590

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Livraison estimée en/au États-Unis, le vendredi 27 décembre 2024

Informations sur le produit

Nom :
H-EGSRNQDWL-OH
Synonymes :
  • NH2-Glu-Gly-Ser-Arg-Asn-Gln-Asp-Trp-Leu-OH
Description :

Peptide H-EGSRNQDWL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-EGSRNQDWL-OH include the following: gp100/pmel 17 is a murine tumor rejection antigen: induction of"self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk , A Tsung, KR Irvine - The Journal of , 1998 - rupress.orghttps://rupress.org/jem/article-abstract/188/2/277/7712 gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of"Self"-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand W Willem, MR Parkhurst, TJ Goletz, K Tsung - The Journal of , 1998 - academia.eduhttps://www.academia.edu/download/41984571/gp100pmel_17_Is_a_Murine_Tumor_Rejection20160203-5394-1pkofkb.pdf Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity UM Abdel-Motal, K Wigglesworth, U Galili - Cancer Immunology , 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-009-0662-2 Vaccination with tumor cells pulsed with foreign peptide induces immunity to the tumor itself TR Schlingmann, FH Rininsland, WC Bartholomae - Clinical , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521661609007001 Antitumor peptide-based vaccine in the limelight T Kumai, H Yamaki, M Kono, R Hayashi, R Wakisaka - Vaccines, 2022 - mdpi.comhttps://www.mdpi.com/2076-393X/10/1/70 T cells modified with CD70 as an alternative cellular vaccine for antitumor immunity SE Lee, AR Shin, HJ Sohn, HI Cho - Cancer Research and , 2020 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373873/ CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular PD Gregor, JD Wolchok, CR Ferrone , H Buchinshky - Vaccine, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X04000933 Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses N Cousin, S Cap, M Dihr, C Tacconi , M Detmar - Cancer Research, 2021 - AACRhttps://aacrjournals.org/cancerres/article-abstract/81/15/4133/670246 Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax® M Mansour, B Pohajdak, WM Kast - Journal of Translational , 2007 - Springerhttps://link.springer.com/article/10.1186/1479-5876-5-20 The good, the bad and the ugly: how altered peptide ligands modulate immunity M Katsara, G Minigo , M Plebanski - Expert opinion on , 2008 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14712590802494501 Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2 M Derouazi, Y Wang, R Marlu, O Epaulard - Bioengineered , 2010 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/bbug.1.1.9482 Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma LV Ly, M Sluijter, SH van der Burg - The Journal of , 2013 - journals.aai.orghttps://journals.aai.org/jimmunol/article/190/1/489/86499 Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm LV Ly, M Sluijter, M Versluis, GPM Luyten - Cancer research, 2010 - AACRhttps://aacrjournals.org/cancerres/article-abstract/70/21/8339/560991 The MHC class I cancer-associated neoepitope Trh4 linked with impaired peptide processing induces a unique noncanonical TCR conformer I Hafstrand, EM Doorduijn, AD Duru - The Journal of , 2016 - journals.aai.orghttps://journals.aai.org/jimmunol/article/196/5/2327/102372 Going Pro to enhance T-cell immunogenicity: E asy as Ï€? HD Hickman , JW Yewdell - European journal of immunology, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201344095 Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles H Yan, G Lin, Z Liu, F Gu, Y Zhang - Acta Biomaterialia, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1742706123001204 Molecular basis for enhanced T-cell recognition and cross-reactivity E Allerbring - 2014 - search.proquest.comhttps://search.proquest.com/openview/db5cc2850745b4dfd296792c34c09473/1?pq-origsite=gscholar&cbl=2026366&diss=y Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin D Sancho , D Mouraca£o-Sa , OP Joffre - The Journal of , 2008 - Am Soc Clin Investighttps://www.jci.org/articles/view/34584 olecular basis for enhanced T-cell recognition and cross-reactivity A Eva - academia.eduhttps://www.academia.edu/download/71465254/Thesis_Eva_Allerbring.pdf

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP45590 H-EGSRNQDWL-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".